-
Modi pitches India as global chipmaking hub
-
King Charles to call on tech giants for 'reassurances' over AI
-
Ukraine plans record defence spending in 2027
-
STARPRIME Responds to Diverging Gold Market Demand with AM/PM Fixing and XAU24/7
-
NASA scan discovers new, 'once in a century' Moon crater
-
Where the US-China tariff row stands ahead of White House summit
-
Most stocks rise as Fed hikes and indicates drive to curb inflation
-
Indonesia cash-for-photos scheme turns animal hunters into protectors
-
UK-Sudanese author pens book to give children 'African history of Africa'
-
Argentine judge orders suspension of Falklands oil project
-
US Congress passes sweeping Russia sanctions bill
-
US Fed raises rates to tackle 'too high' inflation, irking Trump
-
US stocks fall, dollar gains after Fed lifts interest rates
-
Turkey releases 106 protesters, jails more LGBTQ activists
-
US Fed raises rates to tackle 'too high' inflation in move sure to rile Trump
-
Candidate for UN chief calls for AI regulation akin to nuclear weapons
-
US Fed raises rates to battle inflation in move likely to rile Trump
-
'We're losing control,' AI pioneer Yoshua Bengio tells AFP
-
US House faces test on sweeping Russia sanctions bill
-
IR-MED and Dice Technologies Announce collaboration to Evaluate and Advance Pressure-Injury Prevention Platform in Japan
-
British PM says to make 'difficult decisions' as inflation rises
-
Watts, Pitt, Cruz to light up Spain's top film festival
-
Global fuel price demos: a round-up
-
Toogood Gold's Table Mountain Sits in the Shadow of a Nevada Gold Rush
-
Leverate Launches MCP for Traders to Connect AI Assistants With Trading Platforms
-
MEXC July–August Security Report: 38.66M USDT in Risk Funds Intercepted, Futures Insurance Fund Hits 792M USDT
-
MEXC Launches $1M "Discover Your Wall Street DNA" Campaign to Help Traders Find Their Market Fit
-
Emporio Armani names Dario Vitale new creative director
-
Stocks edge higher ahead of US Fed rate call
-
EU to ban social media for under 13s, curb access until 15
-
BASIS.pro Expands On-Chain Infrastructure with XDC Network Partnership and Zypher DAO as Auto Earn Goes Live
-
Wildfires push endangered Sumatran elephants to brink: Indonesian NGO
-
Pickle-flavoured tart? AI inspires Japan's convenience stores
-
Bank of Japan set to raise rates under pressure from inflation, US
-
EU chief hosts Canada's Carney in push to 'deepen' alliance
-
EU chief to unveil social media, gaming curbs for under-15s
-
Meta chief pushes back on AI slowdown calls
-
'Resident Evil' film brings video game's ethos to the big screen
-
US Fed to deliver rate decision with markets betting on hike
-
GA-ASI Mojave First UAS To Complete Battlefield Short Field Ops
-
i-payout Expands U.S. Money Transmitter Licensing Footprint and Advances European EMI Strategy
-
Sanders, Bannon warn of AI dangers in rare US left-right alignment
-
US Senate crypto bill collapses amid partisan deadlock
-
Empty benches as schools reopen in Venezuela's quake-hit Guaira
-
OpenAI, Anthropic and Google are working to create an AI standards body
-
Tiny English village holds 'independence' vote over asylum seeker housing
-
Protesting shepherds, farmers clash with Romanian police
-
US Treasury chief says to meet Chinese counterpart at weekend
-
Foundation Lets Ledger Users Switch to Open Source Without Starting Over
-
BingX Evolves into a Multi-Asset Trading Platform, Connecting Users to Global Opportunities
Google AI tool predicts danger of genetic mutations
Researchers at Google DeepMind, the tech giant's artificial intelligence arm, on Tuesday introduced a tool that predicts whether genetic mutations are likely to cause harm, a breakthrough that could help research into rare diseases.
The findings are "another step in recognising the impact that AI is having in the natural sciences," said Pushmeet Kohli, vice president for research at Google DeepMind.
The tool focuses on so-called "missense" mutations, where a single letter of the genetic code is affected.
A typical human has 9,000 such mutations throughout their genome; they can be harmless or cause diseases such as cystic fibrosis or cancer, or damage brain development.
To date, four million of these mutations have been observed in humans, but only two percent of them have been classified, either as disease-causing or benign.
In all, there are 71 million such possible mutations. The Google DeepMind tool, called AlphaMissense, reviewed these mutations and was able to predict 89 percent of them, with 90 percent accuracy.
A score was assigned to each mutation, indicating the risk of it causing disease (otherwise referred to as pathogenic).
The result: 57 percent were classified as probably benign, and 32 percent as probably pathogenic -- the remainder being uncertain.
The database was made public and available to scientists, and an accompanying study was published on Tuesday in the journal Science.
AlphaMissense demonstrates "superior performance" than previously available tools, wrote experts Joseph Marsh and Sarah Teichmann in an article also published in Science.
"We should emphasize that the predictions were never really trained or never really intended to be used for clinical diagnosis alone," said Jun Cheng of Google DeepMind.
"However, we do think that our predictions can potentially be helpful to increase the diagnosed rate of rare disease, and also potentially to help us find new disease-causing genes," Cheng added.
Indirectly, this could lead to the development of new treatments, the researchers said.
The tool was trained on the DNA of humans and closely-related primates, enabling it to recognize which genetic mutations are widespread.
Cheng said the training allowed the tool to input "millions of protein sequences and learns what a regular protein sequence looks like."
It then could identify a mutation and its potential for harm.
Cheng compared the process to learning a language.
"If we substitute a word from an English sentence, a person that is familiar with English can immediately see whether this word substitution will change the meaning of the sentence or not."
D.Philippon--CPN